MedPath

Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease

Not Applicable
Completed
Conditions
Gastro-esophageal Reflux Disease
Interventions
Procedure: endoscopic mucosal biopsy
Registration Number
NCT02114216
Lead Sponsor
Seoul National University Bundang Hospital
Brief Summary

Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD). We aimed to evaluate TRPV1 and PAR2 mRNA expression levels in the GERD patients and their relationship with endoscopic findings and reflux symptoms.

Detailed Description

All the subjects receive upper GI endoscopy and completed questionnaires about GERD symptoms under the supervision of a well-trained interviewer. Subjects are excluded if there was a history of gastrointestinal surgery, Barrett's esophagus, esophageal motility disorder, duodenal ulcer, benign gastric ulcer or gastroduodenal cancer and if he or she had any history of systemic disease requiring chronic medication (except for hypertension and diabetes mellitus).

The subjects are classified into 3 groups after upper GI endoscopy and completing questionnaires about GERDsymptoms ; ERD(erosive reflux disease), NERD(nonerosive reflux disease) and control group.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
75
Inclusion Criteria
  • subjects who completed upper GI endoscopy and questionnaires about GERD symptoms
Read More
Exclusion Criteria
  • a history of gastrointestinal surgery
  • Barrett's esophagus
  • esophageal motility disorder
  • duodenal ulcer
  • benign gastric ulcer
  • gastroduodenal cancer
  • if he or she had any history of systemic disease requiring chronic medication (except for hypertension and diabetes mellitus).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NERD groupendoscopic mucosal biopsySubjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
control groupendoscopic mucosal biopsySubjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
ERD groupendoscopic mucosal biopsySubjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
Primary Outcome Measures
NameTimeMethod
TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosaup to 24weeks

The primers used in real-time qPCR were designed using PrimerExpress Software V2.0 (Applied Biosystems, Foster City, CA, USA) based on sequence information from the National Center for Biotechnology Information database. Real-time qPCR was performed in triplicate by using a StepOnePlus Real-time PCR (Applied Biosystems) with SYBR Premix Ex TaqTM (Takara Bio, Shiga, Japan) according to manufacturers' instructions and protocols. Thermal cycling was performed as follows: initial denaturation at 95 °C for 10s followed by 40 cycles of 95 °C for 5 s and 60 °C for 33s. Homo b-actin was used as a reference; i.e. each sample was normalized on the basis of its b-actin content. The relative change in all target genes expression was determined by the fold-change analysis.

Secondary Outcome Measures
NameTimeMethod
PAR2 and IL-8 Expression of Esophageal Mucosaup to 24weeks

The primers used in real-time qPCR were designed using PrimerExpress Software V2.0 (Applied Biosystems, Foster City, CA, USA) based on sequence information from the National Center for Biotechnology Information database. Real-time qPCR was performed in triplicate by using a StepOnePlus Real-time PCR (Applied Biosystems) with SYBR Premix Ex TaqTM (Takara Bio, Shiga, Japan) according to manufacturers' instructions and protocols. Thermal cycling was performed as follows: initial denaturation at 95 °C for 10s followed by 40 cycles of 95 °C for 5 s and 60 °C for 33s. Homo b-actin was used as a reference; i.e. each sample was normalized on the basis of its b-actin content. The relative change in all target genes expression was determined by the fold-change analysis.

Trial Locations

Locations (1)

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Gyeonggi-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath